TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports identification of all relevant DNA and RNA variants implicated in various solid tumor types. In addition, it accurately measures key current immuno-oncology biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB). It consolidate Multiple Biomarker Assays into One: Pan-cancer biomarker content aligned with key guidelines and clinical trials. DNA + RNA assay targeting 523 genes for assessment of all DNA and RNA variant types, plus MSI and TMB. Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay.
Bladder Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CTNNB1 (Catenin (cadherin-associated protein), beta 1)
See More ...
Next-Generation Sequencing (NGS)